Novartis
NVS
NVS
1,247 hedge funds and large institutions have $13.6B invested in Novartis in 2024 Q1 according to their latest regulatory filings, with 88 funds opening new positions, 424 increasing their positions, 471 reducing their positions, and 92 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
1,247
Holders Change
-20
Holders Change %
-1.58%
% of All Funds
18.08%
Holding in Top 10
8
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-42.86%
% of All Funds
0.12%
New
88
Increased
424
Reduced
471
Closed
92
Calls
$143M
Puts
$148M
Net Calls
-$5.16M
Net Calls Change
-$19.2M
Top Buyers
| 1 |
CCM
Cullen Capital Management
New York
|
+$125M |
| 2 |
Citigroup
New York
|
+$65.4M |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$64.4M |
| 4 |
MIP
Mondrian Investment Partners
London,
United Kingdom
|
+$57.2M |
| 5 |
GAM
Groupama Asset Management
Paris,
France
|
+$38.4M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$670M |
| 2 |
Dodge & Cox
San Francisco,
California
|
-$78.5M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$71.1M |
| 4 |
Grantham, Mayo, Van Otterloo & Co (GMO)
Boston,
Massachusetts
|
-$56.2M |
| 5 |
Primecap Management
Pasadena,
California
|
-$47.2M |